FDA has grant Breakthrough Therapy Designation for BI 425809 for the treatment of cognitive impairment associated with schizophrenia

This Breakthrough Therapy Designation and Phase III trial initiation for BI 425809, a novel oral glycine transporter-1 (GlyT1) inhibitor, is based on results from the Phase II 1346.9 clinical trial, which reported improved cognition vs placebo in adult patients with schizophrenia

Source:

Biospace Inc.